Search the Newsreel

argenx SE: argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

argenx SE announced the commencement of a tender offer to acquire all outstanding shares of Forte Biosciences, Inc. for $77.00 per share in cash. This acquisition will make Forte Biosciences a wholly-owned subsidiary of argenx. Forte's Board of Directors has recommended that shareholders accept …

REGENXBIO Inc. Quarterly Earnings Report

Form 8K Regenxbio Inc For: 6 August By Investing.com

This article announces the filing of a Form 8K by Regenxbio Inc. on August 6th. The content of the Form 8K itself is not detailed, but the article contextualizes it within broader financial market news and data provided by Investing.com.

REGENXBIO reports Q2 2026: $108.0M revenue, $22.7M net income, cash pro forma >$310M

REGENXBIO announced strong financial results for Q2 2026, with revenues reaching $108.0 million and net income at $22.7 million. The company's cash position, including July 2026 milestone and offering proceeds, stands at over $313 million pro forma. Key upcoming catalysts include a BLA initiation …

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

REGENXBIO Inc. reported its second quarter 2026 financial results, highlighting strong clinical execution and a solid cash runway. Key achievements include the AFFINITY DUCHENNE® trial meeting its primary endpoint, the initiation of the NAAVIGATE study for diabetic retinopathy, and FDA reaffirming the path forward …

REGENXBIO (NASDAQ:RGNX) Issues Earnings Results, Beats Expectations By $0.35 EPS

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and certain officers, alleging federal securities law violations. The lawsuit claims that REGENXBIO made false and misleading statements about the development and commercialization of its gene therapy RGX‑111, …

argenx (ENXTBR:ARGX) After Its Zacks Upgrade What Does The Valuation Narrative Say

RGNX Looks 33.1% Undervalued on GF Value™ Despite Possible Value Trap

Regenxbio Inc (RGNX) is set to report its Q2 earnings, with analysts forecasting a significant year-over-year revenue increase despite caution reflected in recent estimate revisions. While GuruFocus's GF Value™ suggests RGNX is 33.1% undervalued, its GF Score™ of 60 highlights weak financial strength and …

argenx SE (ARGX) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

What Makes Argenx (ARGX) a New Buy Stock

Investors might want to bet on argenex SE (ARGX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. …

Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

Regenxbio Inc expected to post earnings of 6 cents a share - Earnings Preview

Regenxbio Inc. (RGNX) is projected to report earnings of 6 cents per share. This financial forecast is provided as an earnings preview by Refinitiv. The full article is available to TradingView subscribers, offering unlimited access to news sources.

argenx (ARGX) calls September 17 EGM to add two non-executive directors

argenx SE has announced an Extraordinary General Meeting of Shareholders (EGM) for September 17, 2026, in Amsterdam. The primary purpose of the EGM is to vote on the proposed appointments of Mr. Thomas M. Brakel and Mr. Khurem Farooq as non-executive directors to the …

argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026

argenx SE August 3, 2026 – 22:01 PM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of …

Earnings Preview: Regenxbio to Report Financial Results Pre-market on August 06

This article announces that Regenxbio Inc. (RGNX) is scheduled to release its financial results pre-market on August 6. Analysts are expecting a consensus loss per share of -$0.98. The report will likely detail the company's performance and provide insights into its gene therapy programs.

REGENXBIO's second-quarter financial update is set for Aug. 6

REGENXBIO (Nasdaq: RGNX) will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its financial results for the second quarter ended June 30, 2026, and provide operational highlights. Investors and analysts can register for the webcast, with a …

(RGNX) Risk Channels and Responsive Allocation

This article provides a detailed analysis of Regenxbio Inc. (NASDAQ: RGNX), highlighting weak sentiment across all time horizons which supports a short bias. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes …

argenx SE Revenue Breakdown – EURONEXT:ARGX

The article details argenx SE's revenue breakdown, highlighting that the company generated EUR 3.60 billion last year. The Antibody-based Medicines segment was the top performer, contributing EUR 3.68 billion, and the United States was the largest regional contributor with EUR 3.13 billion in revenue.

FTRE vs. ARGX: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. The best …

Euronext NV (EUXTF) (Q2 2026) Earnings Call Highlights: Record Revenue and EBITDA Fueled by ...

This article first appeared on GuruFocus. Revenue: Record underlying revenue and income of EUR544.4 million, up 16.9% year-on-year. Adjusted EBITDA: Reached a record EUR360 million, up 21.1% year-on-year. Adjusted EBITDA Margin: 66.1%, an improvement of 2.3 percentage points compared to Q2 2025. Adjusted Net …

RGNX|Regenxbio Inc|Price:10.180|Chg%:+0.060

The article provides a comprehensive stock analysis of Regenxbio Inc (RGNX) from TradingKey, highlighting its relatively weak fundamentals but significant growth potential. The stock is considered fairly valued, with high institutional ownership and multiple "Buy" ratings from analysts. The company, a clinical-stage biotechnology firm, …

Euronext publishes Q2 2026 results

Euronext Paris SA Euronext publishes Q2 2026 results Euronext delivers the ninth consecutive quarter of double-digit growth, with record results driven by the diversified business model and strategic execution. Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 30 July 2026 – Euronext, …

The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement

3d illustration inflation and deflation graph by Deepadesigns via Shutterstock Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27. FBRX saw significant price movement beginning June 29, weeks before the public announcement. Both FBRX and ARGX exhibited …

REGENXBIO (RGNX) Projected to Post Earnings on Thursday

ARGX|argenx SE|Price:861.810|Chg%:-20.750

This article provides a comprehensive stock analysis of argenx SE (ARGX), highlighting its relatively stable fundamentals, good growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes strong institutional ownership and a "Buy" rating from multiple analysts, with an expected …

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has argenex SE (ARGX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the …

argenx Bets $2.2 Billion on a Vitiligo Breakthrough: What the Forte Biosciences Deal Means for Both Stocks

The biopharma sector is in the middle of a transformation in which macroeconomic pressures and policy developments actively dictate corporate dealmaking. As leading pharmaceutical companies prepare for a $300 billion patent cliff in the second half of the decade, capital allocation has switched sharply …

GreenX Metals (ASX: GRX): Poland Award Enforced in Singapore as Focus Shifts to Copper and Gold

Forte Biosciences (FBRX) Agrees To argenx Takeover As Tender Offer Nears

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. argenx SE has entered into a definitive agreement to acquire Forte Biosciences through a cash tender offer. The boards of both companies have approved the transaction, which …

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Omeros (OMER)

Healthcare analysts have provided insights on Argenx Se (ARGX) and Omeros (OMER). Evercore ISI maintained a Buy rating on Argenx Se with a $1059.00 price target, while Needham maintained a Hold rating on Omeros. Both companies have analyst consensus ratings, with Argenx Se rated …

argenx (ENXTBR:ARGX) Could Be 15% Above Fair Value On The Forte Deal

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. argenx (ENXTBR:ARGX) is back in focus after agreeing to acquire Forte Biosciences in an all cash deal valued at about US$2.2b, centered on Forte's …

argenx signs agreement to buy Forte Biosciences for $2.2bn

argenx has entered a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value. Approved by both companies' boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions. The main asset …

argenx (ENXTBR:ARGX) Stock Looks Fairly Valued With Modest Upside On Earnings

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. argenx stock has delivered a very strong 202.6% return over the past five years, yet its current valuation checks point to a more mixed …

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

(RTTNews) - Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in September; First Tracks, which has been firing on all cylinders since its Nasdaq debut; and Forte Biosciences, following …

Diluted shares outstanding of REGENXBIO, Inc. – HAM:RB0

The article provides a financial snapshot of REGENXBIO, Inc. (HAM:RB0) on TradingView, specifically focusing on its diluted shares outstanding. It notes that the market for HAM:RB0 is currently closed with no trades recorded. The content seems to be a financial data placeholder, indicating where …